Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

2006 ◽  
Vol 21 (11) ◽  
pp. 1998-2001 ◽  
Author(s):  
Theresa A. Zesiewicz ◽  
Kelly L. Sullivan ◽  
Robert A. Hauser ◽  
Juan Sanchez-Ramos
Keyword(s):  
Pilot Study ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Open Label

Voxel-based morphometry at the single subject level: a pilot study in early Huntington's disease

2008 ◽  
Vol 35 (S 01) ◽  
Author(s):  
M Mühlau ◽  
A Wohlschläger ◽  
C Gaser ◽  
M Valet ◽  
S Nunnemann ◽  
...  
Keyword(s):  
Pilot Study ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Single Subject ◽  
Voxel Based Morphometry

scholarly journals Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study

CNS Spectrums ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 164-165
Author(s):  
Samuel Frank ◽  
Claudia M. Testa ◽  
David Stamler ◽  
Elise Kayson ◽  
David Oakes ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Rating Scale ◽  
Study Drug ◽  
Motor Dysfunction ◽  
Open Label ◽  
Entire Treatment Period ◽  
End Of Treatment ◽  
Pharmaceutical Industries

AbstractBackgroundChorea is a prominent motor dysfunction in Huntington’s disease (HD). Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is FDA-approved for the treatment of chorea in HD. In the pivotal, 12-week First-HD trial, deutetrabenazine treatment reduced the Unified Huntington’s Disease Rating Scale (UHDRS) total maximal chorea (TMC) score versus placebo. ARC-HD, an open-label extension study, evaluated long-term safety and efficacy of deutetrabenazine dosed in a response-driven manner for treatment of HD chorea.MethodsPatients who completed First-HD (Rollover) and patients who converted overnight from a stable dose of tetrabenazine (Switch) were included. Safety was assessed over the entire treatment period; exposure-adjusted incidence rates (EAIRs; adverse events [AEs] per person-year) were calculated. A stable, post-titration time point of 8 weeks was chosen for efficacy analyses.ResultsOf 119 patients enrolled (Rollover, n=82; Switch, n=37), 100 (84%) completed ≥1 year of treatment (mean [SD] follow-up, 119 [48] weeks). End of study EAIRs for patients in the Rollover and Switch cohorts, respectively, were: any AE, 2.6 and 4.3; serious AEs, 0.13 and 0.14; AEs leading to dose suspension, 0.05 and 0.04. Overall, 68% and 73% of patients in Rollover and Switch, respectively, experienced a study drug–related AE. Most common AEs possibly related to study drug were somnolence (17% Rollover; 27% Switch), depression (23%; 19%), anxiety (9%; 11%), insomnia (10%; 8%), and akathisia (9%; 14%). Rates of AEs of interest include suicidality (9%; 3%) and parkinsonism (6%; 11%). In both cohorts, mean UHDRS TMC score and total motor score (TMS) decreased from baseline to Week 8; mean (SD) change in TMC score (units) was –4.4 (3.1) and –2.1 (3.3) and change in TMS was –7.1 (7.3) and –2.4 (8.7) in Rollover and Switch, respectively. While receiving stable dosing from Week 8 to 132 (or end of treatment), patients showed minimal change in TMC score (0.9 [5.0]), but TMS increased compared to Week 8 (9.0 [11.3]). Upon drug withdrawal, there were no remarkable AEs and TMC scores increased 4.4 (3.7) units compared to end of treatment.ConclusionsThe type and severity of AEs observed in long-term deutetrabenazine exposure are consistent with the previous study. Efficacy in reducing chorea persisted over time. There was no unexpected worsening of HD or chorea associated with HD upon deutetrabenazine withdrawal.FundingTeva Pharmaceutical Industries Ltd., Petach Tikva, Israel

Longitudinal pilot-study of Sustained Attention to Response Task and P300 in manifest and pre-manifest Huntington's disease

2013 ◽  
Vol 9 (1) ◽  
pp. 10-20 ◽  
Author(s):  
Ellen P. Hart ◽  
Eve M. Dumas ◽  
Erik W. van Zwet ◽  
Karin van der Hiele ◽  
Caroline K. Jurgens ◽  
...  
Keyword(s):  
Pilot Study ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Sustained Attention ◽  
Response Task

scholarly journals QEEG Measures in Huntington’s Disease: A Pilot Study

PLoS Currents ◽  
2010 ◽  
Author(s):  
Aimee M. Hunter ◽  
Yvette M. Bordelon ◽  
Ian A. Cook ◽  
Andrew F. Leuchter
Keyword(s):  
Pilot Study ◽  
Huntington's Disease ◽  
Huntington’S Disease

Contemporary Dance Practice Improves Motor Function and Body Representation in Huntington’s Disease: A Pilot Study

2019 ◽  
Vol 8 (1) ◽  
pp. 97-110 ◽  
Author(s):  
Iris Trinkler ◽  
Philippe Chéhère ◽  
Julie Salgues ◽  
Marie-Lorraine Monin ◽  
Sophie Tezenas du Montcel ◽  
...  
Keyword(s):  
Pilot Study ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Motor Function ◽  
Body Representation ◽  
Contemporary Dance

scholarly journals Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD)

2020 ◽  
Vol 91 (6) ◽  
pp. 622-630
Author(s):  
Kate L Harris ◽  
Wei-Li Kuan ◽  
Sarah L Mason ◽  
Roger A Barker
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Case Reports ◽  
Controlled Trial ◽  
Rate Of Change ◽  
Control Group ◽  
Open Label ◽  
Double Blind ◽  
Before And After ◽  
Rate Of Decline

ObjectivesAlterations in dopamine neurotransmission underlie some of the clinical features of Huntington’s disease (HD) and as such are a target for therapeutic intervention, especially for the treatment of chorea and some behavioural problems. However, justification for such an intervention is mainly based on case reports and small open label studies and the effects these drugs have on cognition in HD remain unclear.MethodsIn this study, we used the Enroll-HD observational database to assess the effects of antidopaminergic medication on motor, psychiatric and cognitive decline, over a 3-year period. We first looked at the annual rate of decline of a group of HD patients taking antidopaminergic medication (n=466) compared with an untreated matched group (n=466). The groups were matched on specified clinical variables using propensity score matching. Next, we studied a separate group of HD patients who were prescribed such medications part way through the study (n=90) and compared their rate of change before and after the drugs were introduced and compared this to a matched control group.ResultsWe found that HD patients taking antidopaminergic medication had a slower progression in chorea and irritability compared with those not taking such medications. However, this same group of patients also displayed significantly greater rate of decline in a range of cognitive tasks.ConclusionIn conclusion we found that antidopaminergic treatment is associated with improvements in the choreic movements and irritability of HD but worsens cognition. However, further research is required to prospectively investigate this and whether these are causally linked, ideally in a double-blind placebo-controlled trial.

Sign in / Sign up

Export Citation Format

Share Document